LPA and atherosclerosis: Studies, in general, support the clinical use of Lp(a) rather than apo(a) isoforms or single nucleotide polymorphisms (SNPs) in predicting the risk of ASCVD (Paré et al., 2019; Trinder et al., 2020a; Page et al., 2020).